[go: up one dir, main page]

EP1765384A4 - Method of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants - Google Patents

Method of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants

Info

Publication number
EP1765384A4
EP1765384A4 EP05750186A EP05750186A EP1765384A4 EP 1765384 A4 EP1765384 A4 EP 1765384A4 EP 05750186 A EP05750186 A EP 05750186A EP 05750186 A EP05750186 A EP 05750186A EP 1765384 A4 EP1765384 A4 EP 1765384A4
Authority
EP
European Patent Office
Prior art keywords
sphingosine kinase
agents
same
cellular activity
activity involving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05750186A
Other languages
German (de)
French (fr)
Other versions
EP1765384A1 (en
Inventor
Stuart M Pitson
Mathew Alexander Vadas
Pu Xia
Paul A Moretti
Tamara Leclercq
Catherine Sutherland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medvet Science Pty Ltd
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004903249A external-priority patent/AU2004903249A0/en
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Publication of EP1765384A1 publication Critical patent/EP1765384A1/en
Publication of EP1765384A4 publication Critical patent/EP1765384A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP05750186A 2004-06-15 2005-06-15 Method of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants Withdrawn EP1765384A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004903249A AU2004903249A0 (en) 2004-06-15 A method of modulating cellular activity and agents useful for same
PCT/AU2005/000856 WO2005123115A1 (en) 2004-06-15 2005-06-15 Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants

Publications (2)

Publication Number Publication Date
EP1765384A1 EP1765384A1 (en) 2007-03-28
EP1765384A4 true EP1765384A4 (en) 2009-07-08

Family

ID=35509458

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05750186A Withdrawn EP1765384A4 (en) 2004-06-15 2005-06-15 Method of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants

Country Status (5)

Country Link
EP (1) EP1765384A4 (en)
JP (1) JP2008502604A (en)
CA (1) CA2569687A1 (en)
MX (1) MXPA06014888A (en)
WO (1) WO2005123115A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012533A1 (en) * 1997-09-08 1999-03-18 Medvet Science Pty. Ltd. A method of modulating cellular activity
WO2003082322A1 (en) * 2002-03-28 2003-10-09 Medvet Science Pty. Ltd. A method of modulating cellular activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ744700A0 (en) * 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
WO2002098458A1 (en) * 2001-06-07 2002-12-12 Medvet Science Pty Ltd Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012533A1 (en) * 1997-09-08 1999-03-18 Medvet Science Pty. Ltd. A method of modulating cellular activity
WO2003082322A1 (en) * 2002-03-28 2003-10-09 Medvet Science Pty. Ltd. A method of modulating cellular activity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LIU H ET AL: "Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, vol. 278, no. 41, 10 October 2003 (2003-10-10), pages 40330 - 40336, XP002986725, ISSN: 0021-9258 *
PITSON STUART M ET AL: "Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation.", THE EMBO JOURNAL 15 OCT 2003, vol. 22, no. 20, 15 October 2003 (2003-10-15), pages 5491 - 5500, XP002529196, ISSN: 0261-4189 *
PITSON STUART M ET AL: "Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling.", THE JOURNAL OF EXPERIMENTAL MEDICINE 3 JAN 2005, vol. 201, no. 1, 3 January 2005 (2005-01-03), pages 49 - 54, XP002529198, ISSN: 0022-1007 *
See also references of WO2005123115A1 *
SUTHERLAND CATHERINE M ET AL: "The calmodulin-binding site of sphingosine kinase and its role in agonist-dependent translocation of sphingosine kinase 1 to the plasma membrane", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, no. 17, April 2006 (2006-04-01), pages 11693 - 11701, XP002529197, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2005123115A8 (en) 2006-04-20
CA2569687A1 (en) 2005-12-29
JP2008502604A (en) 2008-01-31
WO2005123115A1 (en) 2005-12-29
EP1765384A1 (en) 2007-03-28
MXPA06014888A (en) 2007-03-21

Similar Documents

Publication Publication Date Title
EP1720855A4 (en) Inhibitors of akt activity
GB0412974D0 (en) Method of applying active ingredients
ZA200705951B (en) Hydroprocessing catalyst, preparation method thereof and use of same
IL172873A0 (en) System and method for active mobile collaboration
GB2444660B (en) System and methods for distribution of wireless network access
PL1753846T3 (en) Ebullated bed hydroprocessing methods and systems
IL189975A0 (en) Methods of modulating neurotrophin-mediated activity
PL1799269T3 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
IL173174A0 (en) Inhibitors of akt activity
EP1753428A4 (en) Kinase inhibitors as therapeutic agents
IL182763A0 (en) Thrombopoietin activity modulating compounds and methods
SI1725253T1 (en) Medicaments and methods for treating headache
IL182048A0 (en) Method of treating organophosphorous poisoning
AP2006003702A0 (en) Method and arrangement for implementing minimum activity during discontinuous transmission
EP1782821A4 (en) Drug and method for improving brain function
EP1765384A4 (en) Method of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants
EP1852404A4 (en) Anchor fixing agent, anchor fixing agent ampule, and method for fixing anchor
EP1741697A4 (en) Crystal comprising (2r)-2-propyloctoic acid and amine
EP1807454A4 (en) High-activity magnesium-supported catalyst and method of preparing polyolefin using the same
EP1807067A4 (en) Sphingosine kinase activator and skin disease treating agent comprising the same
GB0424565D0 (en) Activity aid
ZA200702538B (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
AU2005903259A0 (en) A method of modulating cellular activity and agents for use therein
AP2007003934A0 (en) Hydrochloride of 4-ÄÄ4-ÄÄ4-(2-cyanoethenyl)-2,6-dimethylphenylÜaminoÜ-2-pyrimidinylÜaminoÜbenzonitrile
AU2004903249A0 (en) A method of modulating cellular activity and agents useful for same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061227

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: VADAS, MATHEW, ALEXANDER

Inventor name: MORETTI, PAUL, A.

Inventor name: LECLERCQ, TAMARA

Inventor name: SUTHERLAND, CATHERINE

Inventor name: XIA, PU

Inventor name: PITSON, STUART, M.

A4 Supplementary search report drawn up and despatched

Effective date: 20090608

17Q First examination report despatched

Effective date: 20090923

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120209